Literature DB >> 12869412

The N314D polymorphism of galactose-1-phosphate uridyl transferase does not modify the risk of ovarian cancer.

W L Alan Fung1, Harvey Risch, John McLaughlin, Barry Rosen, David Cole, Danny Vesprini, Steven A Narod.   

Abstract

It has been proposed that high levels of galactose consumption increase the risk of ovarian cancer. Galactose levels are determined, in part, by the galactose-1-phosphate uridyl transferase gene (GALT). The N314D allele of the GALT gene has been associated with low GALT activity and with an increased risk of ovarian cancer. We screened for the presence of the N314D GALT allele in 891 incident cases of epithelial ovarian cancer and in 364 unaffected female controls. No significant difference in the prevalence of the N314D allele was observed between the cases (18.1%) and the controls (18.7%). The odds ratio associated with the presence of one N314D allele was 0.94 (95% confidence interval (CI), 0.68-1.3; P = 0.70), and the odds ratio associated with two N314D alleles was 1.62 (95% CI, 0.34-7.7; P = 0.54). Subanalyses of the cases by histological type, by age, by ethnic group, by family history, and by BRCA1/2 mutation status did not reveal any significant associations. We conclude that the GALT N314D allele does not predispose to epithelial ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869412

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  2 in total

1.  Duarte galactose-1-phosphate uridyl transferase genotypes are not associated with ovarian cancer risk.

Authors:  Melissa A Merritt; Joanne Kotsopoulos; Daniel W Cramer; Susan E Hankinson; Kathryn L Terry; Shelley S Tworoger
Journal:  Fertil Steril       Date:  2012-06-29       Impact factor: 7.329

2.  Pathogenesis of serous, extra-uterine Müllerian epithelial cancer and therapeutic implications.

Authors:  Louis Dubeau
Journal:  Transl Cancer Res       Date:  2015-02       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.